Silexion Therapeutics appeals Nasdaq delisting; hearing set for June 26, 2025

Silexion Therapeutics Corp

Received Nasdaq delisting notice on May 22 for MVLS <$50M and MVPHS <$15M deficiencies.
Requested hearing on May 28, 2025, staying delisting; hearing scheduled June 26, 2025.
Intends to apply to transfer listing to Nasdaq Capital Market under Equity Standard requiring ≥$2.5M shareholders' equity.
No assurance of success; securities continue trading on Nasdaq under SLXN and SLXNW.

item 8.01item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.